Trial: 202002107

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Phase

I/II (Cancer Control)

Principal Investigator

Thaker, Premal

Disease Site

Other Female Genital; Ovary

Learn more about this study at: clinicaltrials.gov